Nicotinamide riboside for Aging

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
University of Oklahoma Health Sciences Center, Oklahoma City, OK
Aging
Nicotinamide riboside - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Daily consumption of one of the forms of Vitamin B3, the Nicotinamide Riboside (NR), energizes the body and combats cellular aging. This study is designed to test whether NR can also improve brain health and memory.

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

4 Primary · 15 Secondary · Reporting Duration: 8 weeks

8 weeks
Blood collection
Change in Attention
Change in ECG
Change in Episodic Memory
Change in Executive Function
Change in Glycocalyx - perfused boundary region
Change in Language
Change in Processing Speed
Change in Working Memory
Change in arterial stiffness
Change in capillary density
Change in deep tissue oxygen saturation
Change in macrovascular endothelial function
Change in microvascular endothelial function
Change in neuronal activity
Change in neurovascular coupling using functional near infrared spectroscopy (fNIRS)
Change in neurovascular coupling using the dynamic retinal vessel analysis
Change in neurovascular coupling using transcranial Doppler
Change in red blood cell velocity

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

NR
1 of 2
Control
1 of 2
Experimental Treatment
Non-Treatment Group

214 Total Participants · 2 Treatment Groups

Primary Treatment: Nicotinamide riboside · Has Placebo Group · Phase 4

NR
Drug
Experimental Group · 1 Intervention: Nicotinamide riboside · Intervention Types: Drug
Control
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
2014
Completed Phase 2
~90

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks
Closest Location: University of Oklahoma Health Sciences Center · Oklahoma City, OK
Photo of ok university of oklahoma health sciences center 1Photo of ok university of oklahoma health sciences center 2Photo of oklahoma city 3
2002First Recorded Clinical Trial
1 TrialsResearching Aging
418 CompletedClinical Trials

Who is running the clinical trial?

University of OklahomaLead Sponsor
410 Previous Clinical Trials
95,392 Total Patients Enrolled
1 Trials studying Aging
148 Patients Enrolled for Aging
Oklahoma Medical Research FoundationOTHER
20 Previous Clinical Trials
7,693 Total Patients Enrolled
1 Trials studying Aging
148 Patients Enrolled for Aging
University of PennsylvaniaOTHER
1,797 Previous Clinical Trials
36,106,348 Total Patients Enrolled
3 Trials studying Aging
225,168 Patients Enrolled for Aging
Elysium HealthIndustry Sponsor
12 Previous Clinical Trials
1,503 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have adequate hearing and visual acuity to participate in the examinations.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.